Search Results - Stephen I. Pelton

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age by Gary S. Marshall, Stephen I. Pelton, Corwin A. Robertson, Philipp Oster

Connect to this object online.

Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US by Stephen I. Pelton, Joaquin F. Mould-Quevedo, Van Hung Nguyen

Connect to this object online.

Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience by Tomas Mrkvan, Stephen I. Pelton, Javier Ruiz-Guiñazú, Arto A. Palmu, Dorota Borys

Connect to this object online.

A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 an... by Myron J. Levin, Victoria Divino, Maarten J. Postma, Stephen I. Pelton, Zifan Zhou, Mitch DeKoven, Joaquin Mould-Quevedo

Connect to this object online.

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses by David Fisman, Norberto Giglio, Myron J. Levin, Van Hung Nguyen, Stephen I. Pelton, Maarten Postma, Jesús Ruiz-Aragón, Analia Urueña, Joaquin F. Mould-Quevedo

Connect to this object online.